• Bristol Myers Squibb (NYSE:BMY) has entered an enterprise-wide AI partnership with Anthropic to deploy Claude across its global workforce.
• The rollout is designed to support drug discovery, development, and operational workflows across research, regulatory, and commercial teams.
• This agreement represents one of the first large-scale uses of an agentic AI platform across all major functions of a leading biopharmaceutical company.

Bristol Myers Squibb focuses on biopharmaceutical products, with an emphasis on research-driven medicines for serious diseases. The AI partnership with Anthropic sits alongside broader digital efforts across the sector, as large drug companies look for ways to handle complex data, shorten internal cycles, and manage rising development costs.

For investors, an important consideration is how effectively NYSE:BMY can integrate Claude into everyday work to support decision making and execution. The reach of this AI deployment across R&D, regulatory, and commercial processes may influence how projects move through internal stages and how the company allocates capital between competing opportunities.

Stay updated on the most important news stories for Bristol-Myers Squibb by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Bristol-Myers Squibb.

Quick Assessment

• ✅ Price vs Analyst Target: At US$59.55 versus a US$62.96 analyst target, the stock sits about 5.7% below consensus.
• ✅ Simply Wall St Valuation: Simply Wall St estimates Bristol-Myers Squibb is trading about 50.5% below its fair value.
• ✅ Recent Momentum: The stock is up 0.3% over the last 30 days.

There is only one way to know the right time to buy, sell or hold Bristol-Myers Squibb. Head to Simply Wall St's company report for the latest analysis of Bristol-Myers Squibb's fair value.

Key Considerations

• 📊 The Anthropic partnership places AI at the core of research, regulatory work, and commercial execution. This could reshape how projects progress internally.
• 📊 Watch for commentary on productivity, cycle times in drug development, and any disclosed cost or efficiency metrics linked to Claude adoption.
• ⚠️ Analysts currently forecast earnings to decline by an average of 2.7% per year over the next 3 years. Monitor whether AI driven changes alter that outlook over time.

Dig Deeper

For the full picture, including more risks and rewards, check out the complete Bristol-Myers Squibb analysis. Alternatively, you can visit the community page for Bristol-Myers Squibb to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.